



Start of a comparative investigator-initiated study of joint function of Episealer® patients

Episurf Medical (NASDAQ: EPIS B) today announces the start of a comparative investigator-initiated clinical study performed at the Julius Wolff Institute, Charité University Hospital, Berlin. The study with the title "X-Ray Fluoroscopic Analysis of knee joint kinematic in open and closed chain activities in patients with Episealer® Knee Implants" will follow up patients that have undergone an Episealer® procedure during the period 2015-2017 and assess the joint mobility of the treated knee and compare with healthy, non-treated knees as well as benchmark against knees that have undergone total knee arthroplasty (total knee replacement).

"We are honoured that Charité, which was one of the first users of the Episealer®, has taken this initiative to follow up and compare the clinical outcome of the Episealer® procedure. This is the first comparative Episealer® study and we look forward to seeing the outcome. After 6 years' clinical use, we have received very positive feedback from surgeons as well as from many patients. We expect results during 2019 that will confirm that the Episealer® can help restoring the knee function of patients where the treatment alternatives previously have been very limited" says Prof. Leif Ryd, Senior Medical Advisor, Episurf Medical.

"Our clinical program is comprehensive and we are now adding a comparative study. This study is highly interesting, much due to the fact that the results are expected shortly" says Pål Ryfors, CEO Episurf Medical.

For more information, please contact:

Pål Ryfors, CEO, Episurf Medical
Tel: +46 (0) 709 62 36 69
Email: pal.ryfors@episurf.com

About Episurf Medical

Episurf Medical is endeavoring to bring people with painful joint injuries a more active, healthier life through the availability of minimally invasive and personalised treatment alternatives. Episurf Medical's Episealer® personalised implants and Epiguide® surgical drill guides are developed for treating localized cartilage injury in joints. Episurf Medical's µiFidelity® system enables implants to be cost-efficiently tailored to each individual's unique injury for the optimal fit and minimal intervention. Episurf Medical's head office is in Stockholm, Sweden. Its share (EPIS B) is listed on Nasdaq Stockholm. For more information, go to the company's website: www.episurf.com.

This information is information that Episurf Medical AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 08.00 CET on 21 January 2019.